@article{ff113bf271d94c97bb961b254748e32d,
title = "Serum urate, genetic variation, and prostate cancer risk: Atherosclerosis risk in Communities (ARIC) study",
abstract = "Background: Evidence is mounting that intraprostatic inflammation influences prostate cancer development. Uric acid crystals depositing in the prostate could result in injury and inflammation, increasing prostate cancer risk. Methods: Included were 6,574 men ages 45–64 years who enrolled in the Atherosclerosis Risk in Communities study in 1987 to 1989. We used Cox proportional hazards regression to estimate the association of serum urate concentration alone and to improve accuracy, jointly with a genetic risk score (GRS, N ¼ 4,983) derived from variants predictive of urate concentration, with prostate cancer (N ¼ 813) risk. Results: Serum urate concentration or joint categories of urate concentration and GRS were not associated with prostate cancer risk (Ptrend for quartiles ¼ 0.3). Results were generally similar by race and after excluding users of medications that influence uric acid. Conclusions: Serum urate alone and with a urate-associated GRS were not associated with prostate cancer risk. Impact: It is unlikely that circulating urate concentration influences prostate cancer development.",
author = "Anqi Wang and Barber, {John R.} and Adrienne Tin and {De Marzo}, {Angelo M.} and Anna Kottgen and Joshu, {Corinne E.} and Platz, {Elizabeth A.}",
note = "Funding Information: The Atherosclerosis Risk in Communities study has been funded in whole or in part with federal funds from the National Heart, Lung, and Blood Institute, NIH, Department of Health and Human Services (contract nos. HHSN-268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN-268201700004I, and HSN268201700005I), R01HL087641, R01HL059367, and R01HL086694; National Human Genome Research Institute contract no. U01HG004402; and NIH contract no. HHSN268200625226C. Infrastructure was partly supported by grant no. UL1RR025005, a component of the NIH and NIH Roadmap for Medical Research. Studies on cancer in ARIC are also supported by the NCI (U01 CA164975). E.A. Platz was supported by NCI Cancer Center Support Grant P30 CA006973. C.E. Joshu was supported by the Prostate Cancer Foundation. The authors thank the staff and participants of the ARIC study for their important contributions. Cancer incidence data have been provided by the Maryland Cancer Registry, Center for Cancer Surveillance and Control, Maryland Department of Health, Baltimore, MD. We acknowledge the State of Maryland, the Maryland Cigarette Restitution Fund, and the National Program of Cancer Registries of the Centers for Disease Control and Prevention for the funds that helped support the availability of the cancer registry data. Publisher Copyright: {\textcopyright} 2019 American Association for Cancer Research.",
year = "2019",
doi = "10.1158/1055-9965.EPI-19-0161",
language = "English (US)",
volume = "28",
pages = "1259--1261",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "7",
}